---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-097705"
form_type: "8-K"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T09:12:05.322860+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aditxt enters asset purchase agreement to acquire MDNA's early cancer detection platform

## Summary
- Pearsanta to acquire MDNA's early cancer detection IP for $1M cash + 50K Aditxt shares + warrants + Pearsanta preferred valued up to $25M.
- Closing requires Aditxt/Pearsanta to raise at least $10M in debt or equity financing.
- MDNA can terminate if Aditxt fails to pay $500K upfront working capital by December 31, 2023.
- Pearsanta preferred shares designed to provide as-converted value of $25M; additional shares if shortfall.
- Warrants for 50K Aditxt shares exercisable at closing price for 5 years.

## SEC filing metadata
- accession: 0001213900-23-097705
- form_type: 8-K
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390023097705/0001213900-23-097705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390023097705/ea190477-8k_aditxtinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-097705
- JSON: https://secwatch.observer/filing/0001213900-23-097705.json
- Plain text: https://secwatch.observer/filing/0001213900-23-097705.txt

## Key facts
- Material Agreements
  Aditxt, Inc. entered into Purchase Agreement with MDNA Life Sciences, Inc. (effective 2023-12-17).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: MDNA Life Sciences, Inc.
  - Effective: 2023-12-17
  source text: On December 17, 2023, Aditxt, Inc., a Delaware corporation (the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Pearsanta, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Pearsanta ”) and MDNA Life Sciences, Inc., a Delaware corporation (“ MDNA ”), pursuant to which Pearsanta will acquire certain intellectual property and other specified assets relating to MDNA’s early cancer detection platform.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1726711/000121390023097705/0001213900-23-097705-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.